Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction.

Pituitary adenomas account for approximately 10% of intracranial tumors, but little is known of the oncogenesis of these tumors. The identification of tumor-specific genes may further elucidate the pathways of tumor formation. We used complementary DNA microarrays to examine gene expression profiles in nonfunctioning, PRL, GH, and ACTH secreting adenomas, compared with normal pituitary. Microarray analysis showed that 128 of 7075 genes examined were differentially expressed. We then analyzed three genes with unique expression patterns and oncogenic importance by RT-real time quantitative PCR in 37 pituitaries. Folate receptor gene was significantly overexpressed in nonfunctioning adenomas but was significantly underexpressed in PRL and GH adenomas, compared with controls and to other tumors. The ornithine decarboxylase gene was significantly overexpressed in GH adenomas, compared with other tumor subtypes but was significantly underexpressed in ACTH adenomas. C-mer proto-oncogene tyrosine kinase gene was significantly overexpressed in ACTH adenomas but was significantly underexpressed in PRL adenomas. We have shown that at least three genes involved in carcinogenesis in other tissues are also aberrantly regulated in the major types of pituitary tumors. The evaluation of candidate genes that emerge from these experiments provides a rational approach to investigate those genes significant in tumorigenesis.

[1]  K. Mimori,et al.  Analysis of ornithine decarboxylase messenger ribonucleic acid expression in colorectal carcinoma , 1997, Diseases of the colon and rectum.

[2]  M. Makuuchi,et al.  Increased expression of ornithine decarboxylase messenger RNA in human esophageal carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Fukushima,et al.  Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. , 2000, Carcinogenesis.

[4]  I. Vegh,et al.  Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer , 1987, Cancer.

[5]  A. Lima,et al.  Biochemical parameters in the anterior pituitary during the course of tumorigenesis induced by diethylstilbestrol treatment , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  J. Díaz,et al.  Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[8]  N. Oyesiku,et al.  Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors , 2000, Journal of endocrinological investigation.

[9]  R. Fahlbusch,et al.  Expression of menin gene mRNA in pituitary tumours. , 1999, European journal of endocrinology.

[10]  W. Paschen,et al.  Polyamine Metabolism in Experimental Brain Tumors of Rat , 1993, Journal of neurochemistry.

[11]  C. Lavalle,et al.  Prolactin, immunoregulation, and autoimmune diseases. , 1991, Seminars in arthritis and rheumatism.

[12]  W. Mendelson,et al.  Effect of exertion on the stimulation of ornithine decarboxylase activity by growth hormone in rats. , 1989, Life sciences.

[13]  A. Antony,et al.  The biological chemistry of folate receptors. , 1992, Blood.

[14]  W. Nicholson,et al.  Hormonal regulation of renal ornithine decarboxylase activity in the rat. , 1976, Endocrinology.

[15]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[16]  E C Wiener,et al.  Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.

[17]  L. Shantz,et al.  Ornithine decarboxylase as a target for chemoprevention , 1995, Journal of cellular biochemistry. Supplement.

[18]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[19]  H. Snodgrass,et al.  Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr , 2022 .

[20]  J. J. Mukherjee,et al.  The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[21]  H. Hanafusa,et al.  Biological Effects of c-Mer Receptor Tyrosine Kinase in Hematopoietic Cells Depend on the Grb2 Binding Site in the Receptor and Activation of NF-κB , 1999, Molecular and Cellular Biology.

[22]  P. Elwood,et al.  The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. , 1986, The Journal of biological chemistry.

[23]  Brennan,et al.  Association between high levels of ornithine decarboxylase activity and favorable prognosis in human colorectal carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  L. Hood,et al.  Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.

[25]  S. Melmed,et al.  Pituitary Tumor Pathogenesis1 , 1997 .

[26]  G. Vailati,et al.  Polyamines: current review and their perspectives in neurosurgery. , 1982, Journal of neurosurgical sciences.

[27]  S. Melmed,et al.  Genetic basis of endocrine disease: pituitary tumor pathogenesis. , 1997, The Journal of clinical endocrinology and metabolism.

[28]  K. Kovacs,et al.  Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[29]  J. Dussault,et al.  Thyroid hormones modulate ornithine decarboxylase in the immature rat cerebellum. , 1984, Canadian journal of physiology and pharmacology.

[30]  S. Melmed,et al.  Diagnosis and management of nonfunctioning pituitary tumors. , 1996, Annual review of medicine.

[31]  A. Pegg,et al.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.

[32]  W. Gunning,et al.  Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  A. Arnold,et al.  Clinically nonfunctioning pituitary tumors are monoclonal in origin. , 1990, The Journal of clinical investigation.

[34]  C. J. Mathias,et al.  A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. , 1998, Nuclear medicine and biology.

[35]  P. Low,et al.  Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  N. Seiler,et al.  Polyamine metabolism as target for cancer chemoprevention (review). , 1998, International journal of oncology.

[37]  P. Low,et al.  Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. , 2000, Bioconjugate chemistry.

[38]  G. P. Beardsley,et al.  5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. , 1993, The Journal of biological chemistry.

[39]  N. Oyesiku,et al.  Pituitary Adenomas: Screening for Gαq Mutations , 1997 .

[40]  J. Moulinoux,et al.  Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. , 2000, Anticancer research.

[41]  Bettuzzi Saverio,et al.  Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. , 2000 .

[42]  J. Holm,et al.  High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity. , 1999, Archives of biochemistry and biophysics.

[43]  S. Asa,et al.  The MEN-1 gene is rarely down-regulated in pituitary adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[44]  V. Zurawski,et al.  Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.

[45]  R. Thakker,et al.  Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours , 1999, British Journal of Cancer.

[46]  B. Schimmer,et al.  Regulation of ornithine decarboxylase activity by corticotropin in adrenocortical tumor cell clones: roles of cyclic AMP and cyclic AMP-dependent protein kinase. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Mark,et al.  Characterization of Gas6, a Member of the Superfamily of G Domain-containing Proteins, as a Ligand for Rse and Axl (*) , 1996, The Journal of Biological Chemistry.

[48]  P. Low,et al.  Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. , 1999, Nuclear medicine and biology.

[49]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[50]  U. Bachrach,et al.  Polyamines induce malignant transformation in cultured NIH 3T3 fibroblasts. , 1998, The international journal of biochemistry & cell biology.

[51]  L. Marton,et al.  Polyamines as targets for therapeutic intervention. , 1995, Annual review of pharmacology and toxicology.

[52]  J. Ragoussis,et al.  Genomic organization of the human folate receptor genes on chromosome 11q13. , 1992, Genomics.

[53]  W. Nicholson,et al.  Stimulation of adrenal ornithine decarboxylase by adrenocorticotropin and growth hormone. , 1973, Endocrinology.

[54]  Cheryl Schmidt,et al.  Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis , 2000, Oncogene.

[55]  C. Schneider,et al.  The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade , 1993, Molecular and cellular biology.

[56]  S. Bettuzzi,et al.  Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. , 2000, Cancer research.

[57]  S. Asa,et al.  The cytogenesis and pathogenesis of pituitary adenomas. , 1998, Endocrine reviews.